Characterization of a novel extended-spectrum TEM-type beta-lactamase, TEM-164, in a clinical strain of Klebsiella pneumoniae in Tunisia.
Microb Drug Resist, 2009/9;15(3):195-9.
Ben Achour N[1], Mercuri PS, Ben Moussa M, Galleni M, Belhadj O
Affiliations
PMID: 19728777DOI: 10.1089/mdr.2009.0900
Impact factor: 2.706
Abstract
Klebsiella pneumoniae ML1708 exhibited a multiresistance phenotype, including resistance to all beta-lactams tested, chloramphenicol, ciprofloxacin, nalidixic acid, tetracycline, and streptomycin. The double-disk synergy test was positive. ML1708 harbored a 50 kb conjugative plasmid that encoded a beta-lactamase of pI 5.5. The corresponding bla gene was identified by polymerase chain reaction and sequencing as a bla(TEM) gene. The deduced protein sequence revealed a new variant of TEM-1 beta-lactamase designated TEM-164. TEM-164 contains the unusual following mutations: L40V and I279T. These modifications may result in a change of the pI to 5.5 and hydrolyze cefotaxime and ceftazidime.
MeSH terms
Anti-Bacterial Agents; Conjugation, Genetic; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Sequence Analysis, DNA; Tunisia; beta-Lactam Resistance; beta-Lactamases; beta-Lactams
More resources
EndNote: Download